Trials / Sponsors / Implicit Bioscience
Implicit Bioscience
Industry · 11 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury | Phase 2 | 2025-08-15 |
| Active Not Recruiting | Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI) | Phase 1 / Phase 2 | 2025-02-06 |
| Active Not Recruiting | IC14 for Treatment of Acute Decompensated Heart Failure Acute Decompensated Heart Failure | Phase 1 / Phase 2 | 2024-10-17 |
| Suspended | IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy 1 | Phase 1 / Phase 2 | 2024-03-29 |
| Withdrawn | IC14 for Treatment of Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | 2021-08-15 |
| Withdrawn | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis | Phase 2 | 2019-09-01 |
| Withdrawn | A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome Acute Respiratory Distress Syndrome | Phase 2 | 2019-06-01 |
| Withdrawn | IC14 in Adult Patients With Dengue Fever Dengue Fever | Phase 2 | 2019-05-01 |
| Completed | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 1 | 2017-10-01 |
| No Longer Available | IC14 for ALS Patients Expanded Access Amyotrophic Lateral Sclerosis | — | — |
| No Longer Available | Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) COVID, ARDS, Human, Ards | — | — |